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Measles virus (MV) enters cells by attachment of the viral hemagglutinin to the major cell surface receptor CD46
(membrane cofactor protein). CD46 is a transmembrane glycoprotein whose ectodomain is largely composed of four
conserved modules called short consensus repeats (SCRs). We have previously shown that MV interacts with SCR1 and
SCR2 of CD46. (M. Manchester et al. (1995) Proc. Natl. Acad. Sci. USA 92, 2303–2307) Here we report mapping the MV
interaction with SCR1 and SCR2 of CD46 using a combination of peptide inhibition and mutagenesis studies. By testing a
series of overlapping peptides corresponding to the 126 amino acid SCR1-2 region for inhibition of MV infection, two
domains were identified that interacted with MV. One domain was found within SCR1 (amino acids 37 – 56) and another
within SCR2 (amino acids 85 – 104). These results were confirmed by constructing chimeras with complementary regions
from structurally similar, but non-MV-binding, SCRs of decay accelerating factor (DAF; CD55). These results indicate that
MV contacts at least two distinct sites within SCR1-2. q 1997 Academic Press
INTRODUCTION cellular receptor, and subsequently direct fusion with the
cell membrane mediated by the viral fusion protein (F)
Measles virus infections continue to occur despite the
(Wild et al., 1991; Nussbaum et al., 1995). The measles
use of an effective live-attenuated vaccine. Thirty years
virus receptor, CD46 or membrane cofactor protein
after the introduction of vaccination, measles still re-
(MCP), is a transmembrane glycoprotein of MW 57 – 67
mains one of the leading causes of infant death world-
kDa and a member of the Regulators of Complementwide (Bloom, 1989). No specific antiviral therapies for MV
Activation (RCA) superfamily (Liszewski et al., 1991; Doriginfection currently exist. Vaccine failure is often caused
et al., 1993; Naniche et al., 1993; Manchester et al., 1994).by interference from passively acquired maternal anti-
RCA proteins protect the host from autologous comple-body (Gellin and Katz, 1994; Katz and Gellin, 1994). In
ment (Liszewski et al., 1991). CD46, in particular, bindsinfants, maternal antibodies that protect children from
the complement activation fragments C3b and C4b de-measles during the first year of life also prevent replica-
posited on the cell surface and serves as a cofactor fortion of the attenuated vaccine strain. As maternal anti-
their cleavage by the serine protease factor I (Seya etbody wanes, a window of susceptibility occurs where
al., 1986). In this manner further complement depositionwild-type MV can replicate but attenuated vaccines can-
on the cell surface is prevented and complement-depen-not; most MV infections occur within this interval (Katz
dent phagocytosis or lysis of host tissue is prevented.and Gellin, 1994).
The structure of CD46 and its regulatory activity haveThe initial interaction between MV and the host occurs
been well characterized. The extracellular domain offollowing aerosol transmission with the initial infection
CD46 is composed, beginning at the amino terminus,in the oral, nasal, and respiratory mucosa (Norrby and
of four short consensus repeat modules (SCRs). SCROxman, 1990). Virus subsequently disseminates through-
modules are found in all members of the RCA superfamilyout the body via the lymphoid system, and concomitant
and serve as the complement regulatory sites (Liszewskiimmunosuppression can lead to an enhanced morbidity
et al., 1991). Each SCR module is approximately 60 aminoand mortality (Griffin and Bellini, 1996). MV enters cells
acids in length and contains four invariant cysteinesby attachment of the viral hemagglutinin protein (H) to a
forming two disulfide bonds along with a number of other
conserved residues. These framework requirements lead
1 To whom correspondence and reprint requests should be ad- to an approximately 30% amino acid similarity among thedressed.
modules of different RCA family members. A single SCR2 Present address: Institut de Pharmacologie et de Biologie Structur-
ale, CNRS, 205 Route de Narbonne, 31077 Toulouse Cedex, France. forms a beta-barrel with a compact core, and a number
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of exposed, less-conserved regions that are thought to Inhibition of MV infection using peptides
be candidates for ligand-binding (Barlow et al., 1991,
Peptides were diluted to 100 or 10 mM in PBS. All1992). For CD46, C3b- and C4b-binding activity maps
assays were performed in duplicate. Peptides were incu-to SCRs 2, 3, and 4 with cofactor activity particularly
bated with 2 1 105 PFU of sucrose-gradient-purified MVcontributed to by SCR2 (Adams et al., 1991). In contrast,
for 20 min on ice and then incubated with 1 1 105 Helathe MV receptor determinant on CD46 lies in the ectodo-
cells. After 1 hr at 377 the cells were washed four timesmain within SCRs 1 and 2, distinct from the complement
in PBS and then incubated with DMEM containing 7%regulatory domains (Iwata et al., 1995; Manchester et al.,
FBS for 24 hr at 377. Soluble CD46 (sCD46; 0.1 mM) was1995; Buchholz et al., 1996). Both SCR1 and SCR2 mod-
included as a positive control and PBS alone as a nega-ules are required for successful MV binding and infection
tive control for all experiments. Cells were fixed and(Iwata et al., 1995; Manchester et al., 1995; Buchholz et
stained with a polyclonal human antiserum to MV, fol-al., 1996).
lowed by a FITC-conjugated anti-human secondary anti-To further characterize the interaction between MV
body. Percentage of MV-infected cells was determinedand SCR 1-2, an approach that combined peptide inhibi-
by immunofluorescence microscopy. A minimum of fourtion and mutagenesis was used. These mapping studies
fields was counted per sample, and all samples weredefined two regions of CD46 within SCR1-2 that are in-
coded so that the quantitation was unbiased. All datavolved in virus attachment. Further, peptide inhibition ex-
are expressed as the mean for each sample { S.E. Re-periments provide evidence that small soluble peptides
sults were reproducible over four independent experi-based on the linear sequence of the receptor can inhibit
ments.MV infection.
Hemagglutination assay
MATERIALS AND METHODS
The assay was performed according to Norrby andVirus, cells, and media
Gollmar (1975) with the following modifications. Peptides
were diluted to 1004 or 1005 M in 90 ml DMEM, 7% FBS inMeasles virus (MV) Edmonston strain was obtained
individual wells of a round-bottom 96-well plate (Corning,from the ATCC and low-multiplicity passaged stocks of
Corning NY). Edmonston MV (0 – 10 ml/well for controlsvirus were generated and titered on Vero cells. Virus was
or 5 ml/well for peptide assays; 1 1 107 PFU/ml) waspurified by sucrose gradient centrifugation as described
added to each well and incubated for 10 min at 377. After(Manchester et al., 1995) and frozen in aliquots at 0707.
this initial preincubation, 10 ml of a 2% african greenProtein determinations were made of each virus stock
monkey red blood cell suspension (BioWhittaker, Walk-by the Bradford assay. Vero cells were obtained from the
ersville, MD) in DMEM with 7% FBS was added to eachATCC and maintained in M199 medium supplemented
well and gently mixed bringing the total volume to 100with 7% fetal bovine serum and 2 mM L-glutamine. CHO
ml. The microtiter plate was incubated at 377 for 2 hr,cells were grown in Ham’s F12 medium supplemented
allowing the red blood cells to agglutinate and/or settlewith 7% fetal bovine serum, 2 mM L-glutamine, and 0.5
to the bottom of the wells. Hemagglutination was scoredmg/ml Geneticin (G418, Gibco BRL). HeLa cells were
as a uniform distribution of cells over the bottom of themaintained in Dulbecco’s MEM supplemented with 7%
well (/ agglutination) or the presence of a cluster orfetal bovine serum and 2 mM L-glutamine.
dark spot of cells at the bottom of the microtiter wells
(no agglutination).Synthesis and preparation of peptides
The initial set of 27 CD46 peptides corresponding to Construction of CD55 substitutions into CD46
SCR1-2 were synthesized by Chiron Mimotopes (La Jolla,
CA). Each peptide in this set contained an amino-terminal All mutants were constructed in the plasmid vector
pHbApr.1.neo (Gunning et al., 1987). CD46 (BC1 isoform)biotin followed by a four-amino acid (Ser-Gly-Ser-Gly)
spacer. In addition we synthesized 12-amino acid pep- cDNA was previously described (Oglesby et al., 1991). A
PCR mutagenesis strategy was used to introduce CD55tides on an Applied Biosystems synthesizer without the
N-terminal biotin label or spacer. Methods of peptide sequences into the CD46 cDNA. Specifically, for the chi-
mera 1S4, the CD55 amino acid sequence LKGSQWSDI-synthesis and determining peptide purity by HPLC and
mass spectrometry have been described (Gairin and Old- EEFCN was substituted into CD46 SCR1 while deleting
DRNHTWLPVSDDACY. For the chimera 2A6, the CD55stone, 1992; Oldstone et al., 1995). In addition, control
20-mer peptides were used having sequences unrelated amino acid sequence FPVGTVVEYECRPGYRREPSLSPK
was substituted into CD46 SCR2 while deleting FGYQMH-to CD46. All peptides were reconstituted in 20% DMSO
in PBS at a concentration of 2 mM and stored at 0207 FICNEGYYLIGEEI. To do this, oligonucleotide primers were
designed to create two segments for each chimera, 1S4-Aprior to use. Peptides were subsequently diluted in PBS
to the working concentrations indicated. and 1S4-B, or 2A6-A and 2A6-B, each possessing EcoRI
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sites externally and CD55 sequence internally. These were centage of infected cells was quantitated using fluores-
cence microscopy. A total of four fields per sample wassubsequently ligated together to create the CD55 substitu-
tions into CD46. For 1S4, segment A was amplified using as counted and the mean values were indicated. Standard
error for all samples was less than 5%. Concurrent withthe 5* primer GGAATTCCTCTGCTTTCCTCCGGAGAAATA
(CD46 5* untranslated) and the internal phosphorylated the infection, transfectants were stained with monoclonal
antibodies against CD46 and analyzed by flow cytometry3* primer ATCTGACCATTGACTGCCCTTAA GACAAATAG-
TATGGGTGGCAAGAGG (CD46 / CD55). 1S4 segment B to confirm that receptor expression levels were similar
for all transfectants (Cho et al., 1991; Manchester et al.,was created using the external primer GGAATTCCCAAG-
CCACATTGCAATATT AGCTAAGCCACA (CD46 3* untrans- 1995).
Immunohistochemical staining of cells infected withlated region) and the phosphorylated internal primer ATT-
GAAGAGTTCTGCAATAGAGAAACATGT CCATATATACGG MV and cultured in the presence of sCD46 was per-
formed using a Vectastain Elite kit (Vector Labs). Cells(CD55 / CD46). 2A6 segment A was amplified using the 5*
primer GGAATTCCTCTGCTTTCCTCCGGAGAAATA (CD46 on glass coverslips were blocked with avidin and biotin,
stained with a human antiserum to MV, followed by a5* untranslated) and the internal phosphorylated 3* primer
ACGGCACTCATATTCCACAACAGTACCGACTGGAAACT- biotinylated secondary antibody and a streptavidin-per-
oxidase reagent. Recombinant sCD46 was produced inCGTAAGTCCCATTTGCAGGGACTGCTTGGCC (CD46 /
CD55). 2A6 segment B was created using the external CV-1 cells and was provided by CytoMed, Inc. (Cam-
bridge, MA).primer GGAATTCCCAAGCCACATTGCAATATTAGC-
TAAGCCACA (CD46 3* untranslated region) and the phos-
phorylated internal primer CCAGGTTACAGAAGAGAACCT- Molecular modeling of SCR1-2 of CD46
TCTCT ATCACCAAAACTATATTGTGAACTTAAAGGATCA-
An alignment of the amino acid sequences of SCRs15-GTAGCAATTTGGAGC (CD55/ CD46). PCR reactions were
16 from factor H and SCRs 1-2 of CD46 was performedperformed using PFU polymerase (Stratagene, La Jolla, CA)
using Geneworks version 2.2.1 (Intelligenetics, Inc.). Theand reactions were performed as follows. For each PCR
coordinates for factor H SCR15-16 were obtained fromcycle denaturing was at 957 for 2 min and extension at 727
the Brookhaven Protein Data Bank (file 1hfh) (Barlow etfor 2 min. The annealing temperatures were increased as
al., 1993). Model of SCR1-2 based on factor H SCR15-16follows; the first 4 cycles annealing at 377, the next 4 cycles
was generated using the program O (Jones et al., 1991).annealing at 457, and the final 30 cycles annealing at 557.
The PCR products A and B for each chimera were gel
RESULTSpurified and ligated together. A second round of PCR was
performed on the ligation mixture using the CD46 external Peptide mapping of the CD46-MV interaction
primers and the same reaction conditions as above. The
fragment was gel purified and cloned using the TA cloning To determine if MV infection could be blocked by in-
terfering with the MV –receptor interaction, we studiedkit (InVitrogen) and colonies selected on kanamycin. The
entire CD46/CD55 chimera was sequenced to confirm the the ability of soluble CD46 (sCD46) truncated at the trans-
membrane domain or peptides corresponding to SCR1junctions and then inserted as an EcoRI fragment into the
vector pHbapr.1.neo (Gunning et al., 1987). Construction of and SCR2 to block MV infection. For sCD46, serial 10-
fold dilutions of sCD46 or BSA were mixed with 2 1 105the NQ1 mutant has been previously described (Maisner
et al., 1996). Recombinant clones were introduced into CHO PFU of sucrose-gradient purified Edmonston MV. At 24
hr postinfection, cells were stained for MV antigen andcells by cationic lipid transfection (Lipofectin, Gibco BRL,
Bethesda, MD) and colonies selected using 0.5 mg/ml the percentage of infected cells quantitated (Fig. 1A). At
this multiplicity of infection 95% inhibition was seen atG418 (Geneticin, Gibco BRL, Bethesda, MD). Resistant cells
were pooled and sorted for high expression of wild-type or 10 nM with half-maximal inhibition at 0.05 nM. In contrast,
the same concentrations of BSA did not inhibit MV infec-mutant CD46 by flow cytometry. CD46 expressing cells
were tested using a panel of monoclonal antibodies against tion. These results indicate that CD46 need not be
attached to the cell membrane to interact with MV.each SCR to confirm that the protein was properly ex-
pressed at levels similar to wild-type CD46 (Manchester et A significant portion of virus spread in MV infection
occurs via cell – cell transmission (syncytium formation)al., 1995).
rather than production of extracellular virions (Norrby and
Oxman, 1990). To determine whether sCD46 could inhibitInfection of CHO transfectants
syncytium formation in infected cells, confluent mono-
layers of HeLa cells were infected at a m.o.i. of 0.1. AtCHO cells expressing various CD46 and CD55 chime-
ras were infected with purified MV at a m.o.i. of 2. At 24 24 hr postinfection sCD46 was added to the cultures at
concentrations of 1, 10, and 100 nM and incubated for aand 48 hr postinfection, cells were fixed and stained
using a polyclonal human antiserum to MV followed by further 24 hr. In this assay sCD46 reduced the number
of cells involved in syncytia by 10-fold at 100 nM (dataan anti-human FITC-conjugated secondary antibody. Per-
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FIG. 1. Inhibition of MV infection by peptides corresponding to SCR1-2 of CD46. (A) Inhibition of MV infection and cell– cell spread by sCD46.
sCD46 was diluted in PBS, incubated with MV (2 1 105 PFU) for 10 min on ice and then added to 5 1 104 HeLa cells. After 24 hr, cells were fixed
and stained for immunofluorescence as described under Materials and Methods, and percentage of MV-positive cells was determined by fluorescence
microscopy. Values indicated are mean of at least 4 fields { S.E. (B) Twenty-amino-acid overlapping peptides are depicted in single-letter code.
(C) Peptides were tested in nine groups of three for MV-inhibitory activity. Peptides were diluted to 100 mM and then added to MV for 10 min on
ice. The peptide –MV mixture was added to HeLa cells for 1 hr and then washed 3 times with PBS. Infected cells were quantitated by fluorescence
microscopy at 24 hr postinfection and at least 4 fields were quantitated from duplicate samples. Values are expressed as mean { S.E. (D) Peptides
12– 17 and 23 – 27 from C were tested at 100 and 10 mM. Inhibition of MV infection was quantitated at 24 hr postinfection as in C.
not shown), indicating sCD46 can block cell – cell spread terminant lies within SCR1 and SCR2 of CD46 (Man-
chester et al., 1995). Using a series of 20-amino-acidamong already infected cells.
We have previously shown that the MV receptor de- overlapping peptides, the regions within these two
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FIG. 2. Inhibitory activity of small peptide derivatives of peptides 12 and 24. (A) 12 amino acid peptides were synthesized as shown. (B) Peptides
were tested at 100 mM for MV-blocking activity, and values are depicted as means { S.E. Peptide 3 (from B) is a negative control, while 0.1 mM
sCD46 is a positive control for inhibition.
SCRs required for virus binding were mapped. Peptides (SCR1 amino acids 37– 56), the three 12-amino-acid de-
rivatives (12.1, 12.2, 12.3) showed similar inhibition towere designed that spanned the entire 124-amino-acid
SCR1-2 region, overlapping by five amino acids (Fig. peptide 12 (Fig. 2B). The sequence ICDR is common to
all these peptides. Peptide 12 also overlaps a site for1B). Each peptide was initially tested for its ability to
inhibit MV infection at 100 mM. Initially the 27 peptides N-linked glycosylation in SCR1 (asparagine 49). Al-
though the peptides do not contain N-glycans, N-linkedwere tested in groups of 3, using 0.1 mM sCD46 as a
positive control for inhibition (Fig. 1C). At the concentra- glycosylation of the CD46 ectodomain is known to be
important for MV binding and infection (Maisner et al.,tion tested, three groups of peptides inhibited MV infec-
tion with an efficiency similar to (peptides 12 – 14 and 1994; Maisner and Herrler, 1995) (see below). Peptide
secondary structure in this region may also be important24– 26) or lower than (peptides 15 – 17) that of sCD46.
The six other groups did not differ significantly from for binding to MV H.
Within peptide 24 (SCR2 amino acids 85 – 104), threePBS alone or a negative control group composed of
three 20-mer peptides unrelated to CD46 (see Materials smaller peptide derivatives were also synthesized (24.1,
24.2, 24.3). As seen in Fig. 2B, the smaller derivativesand Methods). Peptides from the inhibitory groups were
then tested separately at 100 and 10 mM (Fig. 1D). In containing the N-terminal or central regions (24.1 and
24.2) showed some inhibition of infection, but none ofthis assay, two peptides showed a dose-dependent in-
hibition of MV infection: peptides 12 (IPPLATHTICDR- the smaller derivatives were able to inhibit MV infection
as well as the full-length peptide 24. These results indi-NHTWLPVS) and 24 (FGYQMHFICNEGYYLIGEEI) (Fig.
1D). Peptide 12 corresponds to amino acids 37– 56 cate that the full 20-amino-acid peptide is required for
maximal MV binding but that the amino-terminus is more(numbering from the amino terminus of the mature CD46
protein) in SCR1, spanning the third cysteine. Peptide important for recognition. These results are supported
by the finding that peptide 25 (Figs. 1C and 1D) also24 corresponds to a region spanning the second cys-
teine in SCR2, amino acids 85 – 104. Interestingly, while shows slight inhibition at 100 mM. Peptides in this region
also may have secondary structure that is important forthe combination of peptides 15– 17 showed slight inhibi-
tion (Fig. 1C), none of these peptides showed inhibition recognition by MV H.
Titration of the inhibitory effects of peptides 12 and 24on their own. It may be that each of these peptides has
slight inhibitory activity and the combination is additive. was performed. Peptide 12 showed half-maximal
blocking activity at 50 mM, while peptide 24 showed half-Using peptides 12 and 24 as starting points, 12-
amino-acid-long peptides with 8 residue overlapping maximal blocking activity at 0.1 mM (data not shown).
Peptides 12 and 24 were tested in combination to deter-regions were synthesized (Fig. 2A). Within peptide 12
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using different batches of RBCs. Thus in this assay the
ability of peptide 24 to inhibit hemagglutination (which
measures direct binding of MV H to CD46) is consistent
with the results of the infection– inhibition assay. It is
not clear why peptide 12 cannot block hemagglutination
when it does inhibit infection. It may be that the numbers
of CD46– MV H interactions required for achieving hem-
agglutination may be so high that even a high concentra-
tion of the weaker blocking peptide 12 (100 mM) is not
enough to block the interaction, while the stronger
FIG. 3. Inhibition of hemagglutination activity by CD46-mimetic pep- blocking peptide 24 is able to compete with the CD46-
tide 24. Hemagglutination assay was performed in 96-well round bot- MV H interaction. This is in contrast to the infection–tom plate in duplicate. In the first five pairs of wells no peptide was
inhibition assay (Fig. 1) where a smaller number ofadded, and increasing amounts of MV (1, 2, 5, and 10 ml, corresponding
CD46– MV H interactions are probably sufficient toto 1 1 104, 2 1 104, 5 1 104, and 1 1 105 PFU of MV) was used to
agglutinate the red blood cells. In the last six columns peptides 12, achieve infection and thus peptide 12 can inhibit.
24, and 12 / 24 were added at either 1004 or 1005 M, in combination
with 5 ml (5 1 104 PFU) of MV. Hemagglutination was complete after
Mutagenic analysis of CD46 MV-binding regions2 hr at 377. Whereas agglutinated red blood cells spread in a uniform
layer over the bottom of the well, inhibition of hemagglutination by
To confirm that regions of CD46 identified by peptidepeptide is indicated by a dark circle in the center of the well.
mapping could indeed interact with MV, mutations in
SCR1 and SCR2 were generated and tested for MV re-
ceptor function. In this strategy, a small analogous regionmine if they showed additive or synergistic effects. When
the peptides were tested in combination at 100 mM, they of SCR1 or SCR2 of the complement regulatory protein
decay accelerating factor (DAF; CD55) was substitutedshowed a 15% increase in inhibition compared to either
peptide alone (data not shown). This inhibition was equiv- for the corresponding regions of CD46. CD46 and CD55
share 40% amino acid similarity within SCR1-2. We havealent to the amount of blocking seen using monoclonal
or polyclonal antibodies against CD46, where approxi- previously shown that CD55 does not bind to MV (Man-
chester et al., 1995). Mutants were constructed by PCRmately 95% of MV infection can be inhibited (Manchester
et al., 1994). The remaining 5% of cells are infected inde- mutagenesis based on comparing regions of amino acid
similarity between SCR1-2 of CD46 and CD55. 1S4 sub-pendent of CD46, as CHO cells and other cell types
lacking CD46 can be infected by MV at this low level stitutes the region of CD46 SCR1 corresponding to the
sequences of peptides 12.3 and 13 (Fig. 4) with se-(see Fig. 4 and Dorig et al., 1993; Naniche et al., 1993;
Manchester et al., 1994; Manchester et al., 1995). quences from CD55 (see legend). 2A6 substitutes the
sequence of CD46 SCR2 corresponding to peptides 24,To confirm the inhibitory activity of peptides in a sepa-
rate assay, the ability of MV blocking peptides 12 and 24.1, 24.2, and 24.3 with sequences from CD55. Each of
these plasmids was introduced into otherwise nonper-24 to inhibit hemagglutination was assessed. In the MV
system hemagglutination is defined as the ability for the missive CHO cells, and a receptor-expressing cell line
selected by G418 resistance was sorted for higher ex-MV hemagglutinin glycoprotein to interact with CD46 on
the surface of African green monkey red blood cells pression by FACS. CHO cells expressing wild-type CD46,
wild-type CD55 (Manchester et al., 1995), and a mutation(RBC). MV was mixed with peptides 12 or 24, or the
combination, for 20 min and then incubated with 10 ml of asparagine 49 to glutamine (designated NQ1)
(Maisner et al., 1996) were also tested. CHO cells ex-of a 2% African green monkey red blood cell suspension
bringing the final concentration of RBCs to 0.2%. After 2 pressing each of the receptors shown in Fig. 4 at similar
levels were infected with MV at an m.o.i. of 2 and thehr at 377 hemagglutination activity was assessed. In this
assay, in the absence of hemagglutination, the cells will percentage of infected cells was determined at 24 hr
postinfection. Values are expressed relative to infectioncollect at the bottom of the well and form a dark spot.
When hemagglutination of the RBCs occurs the cells of cells expressing wild-type CD46 that is set at 100%.
As seen in Fig. 4, the 1S4 mutant showed a 50% decreaseform a matte across the bottom of the well. As seen in
Fig. 3, in the absence of peptide increasing amounts of in MV infection compared to cells expressing wild-type
CD46. These results confirm the peptide inhibition stud-virus added to the wells leads to increasing hemaggluti-
nation (columns 1– 5). When peptide 24, the most effec- ies using peptides 12, 12.3, and 13 (Figs. 1C and 2) and
further establish that this region of SCR1 plays a role intive MV blocking peptide was added, hemagglutination
was decreased (compare wells with 5 ml of MV, plus or MV recognition. Since the 1S4 mutant overlapped a site
of N-linked glycosylation, the mutant that substituted as-minus peptide 24). When peptide 12 was added, little or
no decrease in hemagglutination activity was seen. This paragine 49 with glutamine (NQ1) was also tested in this
assay. Removal of the oligosaccharide addition signal atresult was reproducible over four separate experiments,
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FIG. 4. Mutations of CD46 regions corresponding to inhibitory peptides 12 and 24. Schematic diagram indicates wild-type CD46 and CD55
molecules and chimeras. Short consensus repeats are designated 1– 4. Sites of N-linked glycosylation are indicated. For the 1S4 chimera, the
shaded region in SCR1 indicates the sequence DRNHTWLPVSDDACY (amino acids 47 – 61) from CD46 SCR1 was replaced by the sequence
LKGSQWSDIEEFCN from the corresponding region of SCR1 in CD55. For the 2A6 chimera, the shaded region in SCR2 indicates the sequence
FGYQMHFICNEGYYLIGEEI (amino acids 85 –104) from CD46 SCR2 was replaced by the sequence FPVGTVVEYECRPGYRREPSLSPK from the
corresponding region of SCR2 in CD55. The NQ1 mutation substitutes glutamine for asparagine at amino acid 49 and thus removes the consensus
signal for N-linked glycosylation in SCR1. MV infection of CHO cells alone (no receptor) or CHO cells expressing CD46 mutants or controls is
shown on the right. CHO cell lines were sorted by FACS to generate cell populations with equivalent receptor expression on the surface. Cells
were infected in parallel with MV (m.o.i.  2) and percentage of infected cells quantitated at 24 hr postinfection. Percentage of infected cells is
expressed as the mean value with standard error of less than 5% for all samples. Values are normalized for the amount of infection compared to
wild type, set at 100%.
this position led to a minimal (12%) reduction in MV infec- Structural modeling of MV binding domains on CD46
tion (Fig. 4), indicating that this oligosaccharide is not
An amino acid sequence alignment was made be-required for MV attachment to the receptor and confirm-
tween CD46 SCRs 1-2 and factor H SCRs 15-16. Theseing the results of Maisner et al. (1996).
two regions have 42% amino acid similarity (data notWhen peptide 24 sequences from SCR2 were replaced
shown). Using the known NMR structure of factor H SCRsby CD55 sequences, a 94% reduction in MV infection was
15-16 as a guide (Barlow et al., 1993), the SCRs 1-2 ofseen (Fig. 4). This is similar to the level of MV infection of
CD46 were modeled using the program O (Jones et al.,CHO cells (no receptor, 93% reduction from wild-type)
1991) (Figs. 5A and 5B). A stereo view (A) and space-CHO cells expressing CD55 alone (97% reduction). This
filling model (B) of CD46 SCR1-2 are shown in Fig. 5.is also comparable to the reduced amount of MV infec-
Orientation of the two modules relative to each other wastion seen when CD46 SCR2 is completely removed (Man-
consistent with that of the factor H structure (Barlow etchester et al., 1995). The profound loss of receptor func-
al., 1993). In this orientation, identification of the two MVtion seen with this chimera is consistent with the inhibi-
binding domains (peptide 12, amino acids 37– 56 oftion seen with peptide 24 both in the peptide inhibition
SCR1, and peptide 24, amino acids 85– 104 of SCR2)assay and in the hemagglutination assay (Figs. 1– 3).
depicted in blue indicate that these two regions are onAgain these results confirm the role of this region of
SCR2 in interacting with MV. the surface and lie on the same face of the molecule.
FIG. 5. Model of CD46 with MV binding regions. (A) A stereoview of the ribbon diagram of the CD46 model. Amino (N) and carboxyl (C) termini
are indicated. Regions corresponding to peptides 12 (SCR1, upper module) and 24 (SCR2, lower module) are color-coded in blue and the rest of
the model in red. The ribbon diagrams were generated by the program RIBBONS (Carson, 1991). (B) Space-filling drawing of the CD46 SCR1-2
model with the same color scheme as in (A), with all atoms shown as spheres of 1.8 A˚. The MV binding regions corresponding to peptides 12 and
24 shown in blue lie on the same face of the molecule. The space-filling drawing was made with the program MidasPlus (Ferrin et al., 1988; Huang
et al., 1991). (C) Schematic model of CD46 on the cell surface interacting with MV glycoproteins on the virion membrane. MV-binding regions are
depicted in blue. SCRs, N-linked oligosaccharides, and cytoplasmic regions of CD46 are indicated. MV H and F glycoproteins are depicted on the
virion surface.
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DISCUSSION modeling of SCR1-2 of CD46, no additional conforma-
tional changes from factor H (tilt angle or degree of twist
Here we further define regions of CD46 SCR1 and for the two SCRs relative to one another) were required
SCR2 that are involved in MV binding and infection. The to achieve proximity of the MV binding domains on the
combination of peptide mapping and mutagenesis stud- same face of the molecule. Based on the modeling stud-
ies demonstrate that MV contacts at least two distinct ies of SCR1-2 we suggest that the modules are oriented
regions within SCR1-2 and that peptides corresponding relative to one another such that the peptide binding
to these regions inhibit MV infection. Our data also sup- regions occupy positions on the same face of the mole-
port the finding of Seya et al. (1995) and Devaux et al. cule and that the module pair forms a binding pocket
(1996), showing that a soluble form of CD46 can block that allows MV H to dock against this region (Figs. 5A
MV infection. and 5B).
SCRs are a highly conserved structural motif among A model for the interaction of MV with CD46 is shown
members of the RCA superfamily and are also found in in Fig. 5C. The MV H and F proteins are shown on the
many other proteins such as interleukin 2 receptor, factor virion membrane. While little is known about the structure
XIIIb, and several viral proteins (Hourcade et al., 1989). of MV H it has been suggested that the CD46 binding
While structural information on CD46 is not available, domain lies within amino acids 451– 505 (Hummel and
solution NMR data on two SCRs from factor H shows Bellini, 1995), with particular contribution by amino acids
the basic SCR structure to be a compact beta-barrel of 451 and 481 (Lecouturier et al., 1996). While CD46 is
approximately 15 by 30A˚, with disulfide bonds between depicted here as a monomer on the cell surface this has
the first and third cysteines (C1 – C3) and between the not yet been directly determined. Nevertheless, Devaux
second and fourth cysteines (C2 – C4) (Barlow et al., 1991, et al. have shown that when studying purified proteins
1992). The more conserved regions of the module form in solution one dimer of MV H interacts with one mono-
the b-barrel core, while the less well conserved regions mer of CD46 (Devaux et al., 1996).
generally form exposed regions. It is thought that all Maisner et al. (1994; Maisner and Herrler, 1995)
SCRs have this basic structure. showed that MV binding to CD46 is dependent upon N-
Mapping of the receptor –ligand interactions for other glycans, but that these N-glycans need not be complex
members of the RCA family suggest that most comple- oligosaccharides. These findings suggest the oligosac-
ment ligands interact with the exposed loops, rather than charides contribute to conformation of the virus binding
residues that make up the conserved hydrophobic core site but not specifically to recognition by MV. Interest-
(Krych et al., 1991, 1994; Molina et al., 1994, 1995). Our ingly, while the oligosaccharide in SCR1 is not required
data show that MV interacts with at least two regions for MV binding, the oligosaccharide in SCR2 is required
that are most likely on the surface, but are not necessarily for binding (data not shown and Maisner et al., 1996).
in nonconserved domains. These specific interactions The oligosaccharide in SCR2 may be required for main-
with portions of SCR1-2 provide a means for MV to dis- taining the conformational angle or reducing flexibility
criminate between CD46 and other complement recep- between SCR1-2 and therefore providing a more rigid
tors with similar structures. Although peptides can form docking site for MV H.
secondary structure they may not assume the conforma- Despite 40 million infections per year, no specific anti-
tion that is found within the complete polypeptide. Thus MV therapeutic strategies exist. Our studies indicate use
MV may interact with additional structural determinants of small molecules mimicking CD46 may be an effective
in SCR1-2 that peptide mapping studies cannot identify. strategy for anti-MV therapies. For example, peptides 12
Further mutagenic analysis may reveal other regions im- and 24, although their blocking activity is only in the
portant for the MV –CD46 interaction that the peptide millimolar range, possibly represent starting candidates
mapping has not. for the development of more potent therapeutic mole-
What tertiary structure does the MV H recognize, and cules. MV infection is typically self-limiting, but complica-
how are the SCRs arranged relative to one another? Anal- tions such as pneumonia and immunosuppression en-
ysis of single and paired SCRs from factor H show that hance morbidity and mortality (Griffin and Bellini, 1996).
SCRs are not arranged in a strictly linear fashion, but Karp et al. (1996) have shown that ligand binding to CD46
instead an SCR pair forms an angle of approximately induces downregulation of IL-12 production by mono-
1007, with 131 { 417 of twist about the long axis of the cytes, potentially leading to immunosuppression. This IL-
module (v) for the second SCR of a pair relative to the 12 downregulation might be avoided by using molecules
first SCR (Barlow et al., 1993; Molina et al., 1995). It is that block the MV– CD46 interaction. Finally, it has been
predicted that for a particular pair of modules, the degree proposed that the interaction between MV H and CD46
of angle and twist for adjacent SCRs will be unique and that leads to downmodulation of CD46 from the cell sur-
will be determined by the number and composition of face also renders cells more susceptible to complement
the residues that form the interface between a particular deposition and lysis (Krantic et al., 1995; Schneider-
Schaulies et al., 1995, 1996; Schnorr et al., 1995). Re-SCR pair (Barlow et al., 1993; Molina et al., 1995). For
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lation of antisense transcripts. Proc. Natl. Acad. Sci. USA 84, 4831–agents that specifically block the MV H – CD46 interaction
4835.might also block downmodulation and preserve cells
Hourcade, D., Holers, V. M., and Atkinson, J. P. (1989). The regulators
from complement-mediated lysis without otherwise per- of complement activation (RCA) gene cluster. Adv. Immunol. 6, 381–
turbing the complement system. 416.
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